🇺🇸 PTCT — PTC Therapeutics, Inc.

Salud Compra
← Volver

Precio actual

68,12 USD

Máx. histórico

89,55

117 días

Caída desde máximo

-23,93%

Rango 52 semanas

58,80 – 90,87

Variación hoy

+11,89%

Cierre anterior

60,88

Rango de hoy

63,16 – 68,72

Volumen hoy

2.643.738

Peor caída histórica

-94,60%

17/03/2015 → 03/11/2016

Recuperado en 3305 días

Volatilidad anualizada ⓘ

72,99%

Información
Nombre completo
PTC Therapeutics, Inc.
Divisa
USD
Mercado
NasdaqGS
Sector
Salud
Industria
Biotechnology
Empleados
991
PER ⓘ
—
Dividend yield
0,00% (puede no estar actualizado)
Precio objetivo analistas
100,47 USD (puede no estar actualizado)
Primera cotización
20/06/2013
Precio actualizado
hace 7 horas
Sobre la empresa

PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to children and adults living with rare disorders in the United States and internationally. The company provides Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children. Its development pipeline products include Sepiapterin for the treatment of phenylketonuria; PTC518 splicing platform, which is being developed for the treatment of Huntington's disease; and inflammation and ferroptosis platforms, including vatiquinone to treat Friedreich's ataxia. The company distributes its products through third-party distributors. It has collaborations with F. Hoffman-La Roche Ltd., Hoffman-La Roche Inc., the SMA Foundation, National Taiwan University, Akcea Therapeutics, Inc., and Shiratori Pharmaceutical Co., Ltd. The company has license and collaboration agreement with Novartis Pharmaceuticals Corporation to develop PTC518 Huntington's disease program. It markets Upstaza, a gene therapy with the brand name Kebilidi in the United States. PTC Therapeutics, Inc. was incorporated in 1998 and is headquartered in Warren, New Jersey.

Rentabilidad mensual
Evolución
Histórico día a día
Fecha Apertura Máximo Mínimo Cierre Variación Volatilidad día Volumen
12/01/2015 54,00 54,18 52,52 53,70 +0,15% 3,07% 201.900
09/01/2015 54,45 54,45 51,81 53,62 -1,03% 4,85% 177.200
08/01/2015 53,95 56,56 53,09 54,18 +1,82% 6,43% 290.800
07/01/2015 51,90 53,89 51,31 53,21 +4,19% 4,97% 276.500
06/01/2015 53,19 54,15 49,93 51,07 -3,06% 7,93% 275.100
05/01/2015 50,59 53,96 50,17 52,68 +3,29% 7,49% 352.400
02/01/2015 52,53 52,81 50,03 51,00 -1,49% 5,29% 280.400
31/12/2014 52,84 54,19 51,61 51,77 -1,95% 4,88% 279.000
30/12/2014 53,59 54,50 52,58 52,80 -1,53% 3,58% 185.500
29/12/2014 53,07 54,50 52,32 53,62 +0,47% 4,10% 127.800
26/12/2014 51,67 54,04 51,40 53,37 +3,31% 5,12% 155.400
24/12/2014 50,86 53,29 50,84 51,66 +1,49% 4,83% 210.900
23/12/2014 56,59 56,59 50,50 50,90 -7,87% 10,76% 638.500
22/12/2014 55,74 57,35 54,70 55,25 -2,54% 4,75% 349.600
19/12/2014 57,03 57,50 54,88 56,69 +3,15% 4,59% 1.629.300
18/12/2014 54,70 54,99 52,60 54,96 +8,02% 4,37% 510.300
17/12/2014 48,07 51,27 48,07 50,88 +5,08% 6,66% 398.300
16/12/2014 50,00 50,76 48,39 48,42 -4,02% 4,74% 462.900
15/12/2014 56,12 56,99 50,15 50,45 -9,70% 12,19% 600.900
12/12/2014 54,60 56,84 53,77 55,87 +0,98% 5,62% 363.900
11/12/2014 54,01 56,46 53,87 55,33 +3,75% 4,79% 558.300
10/12/2014 55,01 55,85 53,02 53,33 -3,04% 5,14% 586.700
09/12/2014 52,25 56,98 50,41 55,00 +5,18% 12,57% 1.003.800
08/12/2014 49,64 53,23 49,64 52,29 +5,64% 7,22% 492.400
05/12/2014 47,20 49,78 47,20 49,50 +5,52% 5,47% 430.900
04/12/2014 47,75 50,30 46,42 46,91 +0,02% 8,13% 768.100
03/12/2014 48,51 48,64 45,70 46,90 -1,84% 6,06% 244.700
02/12/2014 43,10 48,67 42,51 47,78 +10,55% 14,29% 548.600
01/12/2014 44,78 45,18 43,05 43,22 -3,42% 4,76% 207.800
28/11/2014 45,21 46,59 44,56 44,75 -0,16% 4,49% 131.100